



Prevalence of HCV antibodies in

hemodialysis patients in Beni Suef

governorate

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

Thesis

Submitted for partial fulfillment for master degree
in Nephrology

By

Tarek Atef Taha

M.B.B.Ch.

Under supervision of

PROF.DR. GAMAL ELSAYD MADY

Prof. of internal medicine & nephrology

Ain shams university

DR. MONA HOSNEY ABDEL-SALAM

Ass.Prof of internal medicine & nephrology

Ain shams university

DR. WALEED ANWER ABDEL- MOHSEN

Lecturer of internal medicine & nephrology

Ain shams university

Faculty of Medicine
Ain Shams University
2012



This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

مدى انتشار مصادات الانهباب الكبدى اليباوى
الفيروسى سى بين مرضى الغسيل الكلوى فى
محافظة بنى سويف

ستير فى امراض الكلى

الطبيب/ طارق عاطف طه
بكالوريوس الطب و الجراحة

ا.د/جمال السيد ماضى
استاذ الباطنة و الكلى جامعة عين شمس

ا.د/منى حسنى عبد السلام
استاذ مساعد الباطنة و الكلى جامعة عين شمس

د/ وليد انور عبد المحسن
عين شمس

كلية الطب
جامعة عين شمس
القاهرة

HCV infection still remains a major health problem that can cause substantial liver related morbidity and mortality in patients with ESRD.

The global prevalence of hepatitis C virus (HCV) infection estimated to be around 1.6 - 3% worldwide, Egypt has the largest epidemic of hepatitis C virus (HCV) in the world with 10 - 13% of the population infected with HCV.

The prevalence of anti-HCV positivity among dialysis patients varies in different countries from (3%-75% worldwide), unfortunately Egypt also is considered one of the countries with the highest prevalence.

This work is a part of project aiming to survey about HCV among HD patients, assessing its prevalence, seroconversion and study risk factors associated with HCV seroconversion among hemodialysis patients in Egypt. This project is modulated by the nephrology department, Ain Shams University.

This study was conducted upon 937 ESRD patients on regular HD sessions attending 11 different HD units in Beni Suef governorate, districts included in this study were El-Fashn El-wasta, Beni suef, Ehnasia, Beba, Smosta and Naser.

All patients were evaluated using a questionnaire form for assessment of risk factors claimed to be responsible for HCV seroconversion among HD patients such as; age by years, gender, duration of hemodialysis, previous blood transfusion, previous surgery, isolation procedures in the centers, infection control measures, dialysis in



This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَمَنْ يَتَّقِ اللَّهَ يَجْعَلْ لَهُ مَخْرَجًا
(٢) وَيَرْزُقْهُ مِنْ حَيْثُ لَا يَحْتَسِبُ

*First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof.dr. Gamal Elsayd Mady**, Professor of Internal Medicine and Nephrology, Faculty of Medicine- Ain Shams University for his meticulous supervision, for his kind guidance, valuable instructions and generous help.*

*I am deeply thankful to **Dr. Mona Hosney Abdel-Salam** Ass.Professor of Internal Medicine and Nephrology Faculty of Medicine- Ain Shams University for her great help, outstanding support, active participation and guidance.*

*Special thanks are due to **Dr. Walid Anwer Abdel- Mohsen**, Lecturer of internal medicine and nephrology ,Faculty of Medicine- Ain Shams University for his sincere efforts, fruitful encouragement.*



This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

I want to thank all my staff, my family, my colleagues and my patients without their help this work could not have been completed.

Tarek Atef



List of Abbreviations

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

ALT	<i>Alanine Aminotransferases</i>
AST	<i>Aspartate Aminotransferases</i>
C	<i>Complement</i>
CDC	<i>Center for Diseases Control and Prevention</i>
CKD	<i>Chronic kidney disease</i>
DM	<i>Diabetes mellitus</i>
DOPPS	<i>Dialysis outcomes and practice patterns study</i>
EHMs	<i>Extrahepatic manifestations</i>
EIA	<i>Enzyme immunoassay</i>
ELISA	<i>Enzyme Linked Immunosorbent Assay</i>
ESRD	<i>End stage renal disease</i>
ETR	<i>End-of treatment response</i>
FDA	<i>Food Drug Administration</i>
GFR	<i>Glomerular filtration rate</i>
HCV	<i>Hepatitis C Virus</i>
HBV	<i>Hepatitis B Virus</i>
HbA1c	<i>Glycosylated hemoglobin</i>
HCC	<i>Hepatocellular carcinoma</i>
HCWs	<i>Health care workers</i>
HD	<i>Hemodialysis</i>
HIV	<i>Human Immunodeficiency Virus</i>
HTN	<i>Hypertension</i>
Ig	<i>Immunoglobulin</i>
K/DOQI	<i>kidney Disease Outcomes Quality Initiative</i>
IFNs	<i>Interferons</i>
LPDs	<i>Lymphoproliferative disorders</i>
MC	<i>Mixed cryoglobulinemia</i>



List of Abbreviations (Cont.)

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

Maintenance Hemodialysis

MPGN *Membranoproliferative glomerulonephritis*

NCR *Non coding region*

NIH *National Institute of Health*

NK *Natural killer*

NKF *National Kidney Foundation*

PCR *Polymerase Chain Reaction*

PD *Peritoneal dialysis*

PEG-IFN *Pegylated interferon*

RCTs *Randomized controlled trials*

RF *Rheumatoid factor*

RIBA *Recombinant Immunoblot Assay*

SVR *Sustained viral response*

TMA *Transcription mediated amplification*

TLR3 *Toll like receptors*

WHO *World Health Organization*



Introduction

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

More than 100 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for over 1 million deaths from cirrhosis and primary liver cancers (**Poynard et al, 2003**).

Hepatitis C is the most common cause of chronic viral liver disease in haemodialysis patients (**Hinrichsen et al., 2002**)

Both HCV and chronic renal disease are common and potentially serious medical problems throughout the world. In recent years, it has become clear that these two conditions are linked in several important ways. Indeed, some forms of renal disease are precipitated by HCV infection (**Meyers et al, 2003**). However, patients with end-stage renal disease (ESRD) are at increased risk for acquiring HCV infection (**Meyers et al, 2003**)

Hemodialysis patients are at particular high risk for bloodborne infections because of prolonged vascular access and potential for exposure to contaminated equipment. It has been estimated that, among patients on hemodialysis, the prevalence of HCV infection varies greatly, from less than 5% to nearly 60% according to different areas of the world (**Furusyo et al, 2000 and Tang and Lai , 2005**).

Regardless of the geographic location, however, the prevalence is consistently associated with patient age and the number of transfused blood products (**Tang and Lai , 2005**)



HCV infection is also a major health care issue in renal
This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message
infection before transplantation is reported as high as 40% (Bloom and
Lake, 2006).

The prevalence of HCV infection among HD patients varies from country to country and from one center to another. The reported prevalence of HCV infection among dialysis patients in developed countries ranges from 3.6 to 20%; (Jadoul et al., 2004). It is much higher in developing countries (Jaiswal et al., 2002). The prevalence of anti-HCV among dialysis patients was 8.4% in the United States (2000) 43.9% in Saudi Arabia (2001), 30% in India (2002), and 41% in Turkey (2001) (Tokars et al., 2002). In Egypt according to the Egyptian renal registry the prevalence is 52.1 % (Afifi 2009).



<i>Introduction.....</i>	<i>7</i>
<i>Aim of the work.....</i>	<i>15</i>
<i>Review of Literature</i>	
<i>HCV overview.....</i>	<i>17</i>
<i>HCV-related kidney diseases</i>	<i>46</i>
<i>Infection control.....</i>	<i>74</i>
<i>Patients and Methods.....</i>	<i>88</i>
<i>Results</i>	<i>92</i>
<i>Discussion</i>	<i>111</i>
<i>Summary</i>	<i>120</i>
<i>Conclusion.....</i>	<i>123</i>
<i>Recommendations</i>	<i>125</i>
<i>References</i>	<i>128</i>
<i>Arabic Summary.....</i>	<i>147</i>

Fig. (1):	General view on the natural history of HCV.....	18
Fig.(2):	Sources of infection for hepatitis C.....	21
Fig.(3):	Current model of the HCV lifecycle.....	28
Fig.(4):	Multifactorial mechanisms leading to hepatitis steatosis in HCV.....	29
Fig. (5):	Schematic representation of EHM categories.....	36
Fig. (6):	Stopping rule for the treatment of chronic HCV.....	41
Fig. (7):	Pathogenesis of Circulatory Abnormalities and Renal Failure in Cirrhosis.....	55
Fig. (8):	An algorithmic Approach to the treatment of HCV realeated MC.....	60
Fig. (9):	Hand washing with soap&water	79
Fig. (10):	Hand Hygiene with alcohol	80
Fig. (11):	How to don and remove sterile gloves	81
Fig. (12):	How to don and remove non-sterile gloves.....	82
Fig.(13):	Plan of hemodialysis unit.....	86



List of Tables

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

Table (1):	Annual reports of Egyptian renal registry from 1996 to 2008	20
Table (2):	HCV-related extrahepatic manifestations.....	34.
Table (3):	Prevalence of clinical extrahepatic manifestations.....	35
Table (4):	Monitoring parameters for Interferon-based therapies with or without Ribavirin.....	45
Table (5):	Main types of renal failure in patients with cirrhosis	52
Table (6):	Recommended Treatment of HCV Infection in Patients With CKD.....	58
Table (7):	Specific therapies for the Hepatorenal Syndrome in patients with cirrhosis.....	61
Table (8):	Core infection prevention and control interventions for health-care facilities.....	83
Table (9):	The questionnaire form used in this study.....	91
Table (10):	Gender distribution in the study.....	94
Table (11):	Age distribution by years among HD patients.....	95
Table (12):	HCV prevalence at start of dialysis.....	96
Table (13):	HCV prevalence by the time of the study.....	97



List of Tables (Cont.)

This file was edited using the trial version of Nitro Pro 7

Buy now at www.nitropdf.com to remove this message

Table (14): prevalence of HCV seroconvergence.....	98
Table (15): Prevalence of chronic viral hepatitis among HD patients; (HCV, HBV and HCV/HBV co-infection) at start of dialysis.....	99
Table (16): Correlation between HCV sero-converted and HCV negative cases regarding age and Duration of HD	100
Table (17): causes of renal failure in the studied group.....	101
Table (18): Comparison between HCV sero-converted and HCV free cases regarding Blood transfusion.....	102
Table (19): Comparison between HCV sero-converted and HCV free cases regarding previous surgery.....	103
Table (20): Comparison between HCV sero-converted and HCV free cases regarding Switching Dialysis.....	103
Table (21): Comparison between HCV sero-converted and HCV free cases regarding application of infection Control.....	104
Table (22): Comparison between HCV sero-convertered and HCV free cases regarding isolation procedures.....	105
Table (23): Comparison between HCV seroconverted and HCV free cases regarding their gender.	105



nitro

List of Tables (Cont.)

This file was edited using the trial version of Nitro Pro 7
Buy now at www.nitropdf.com to remove this message

Table (24): Comparison between HCV seroconverted and HCV free cases regarding HBV.....	106
Table (25): Comparison between HCV seroconverted and HCV free cases regarding Family history of HCV.....	107
Table (26): Comparison between HCV seroconverted and HCV free cases regarding history of Shistosomiasis.....	107
Table (27): Categorical risk factors for seroconversion – Univariate analysis.....	109
Table (28): Risk factors for seroconversion – Multivariable analysis using logistic regression.....	110